Feedback PLC First sale of TexRAD in South Korea (3371L)
27 April 2015 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 3371L
Feedback PLC
27 April 2015
27 April 2015
Feedback plc
("Feedback" or the "Company")
First sale of TexRAD in South Korea
Feedback plc (AIM: FDBK), the medical imaging software company,
announces the first sale for research purposes of Feedback's TexRAD
texture analysis software in South Korea. As part of the new PET-CT
scanner installed by Siemens at Seoul National University Bundang
Hospital, (SNUBH), TexRAD software was purchased for use by the
Nuclear Medicine department at SNUBH to undertake research studies
in cancer and other diseases. Uniteko Co.,Ltd are the Siemens
PETNET Korea Co., Ltd ("Siemens") authorised distributor who
facilitated the purchase and installation process of TexRAD
research software at SNUBH on behalf of Siemens.
SNUBH is one of the specialty branches of the Seoul National
University Hospital system. It is South Korea's national medical
research hospital dedicated to the study and treatment of geriatric
diseases. When SNUBH opened in 2003, it was the first fully
digital, paperless hospital in the Asia-Pacific region. It is now
the digital cornerstone of the South Korean national healthcare
system and is a world leader in the use of data to inform clinical
decision-making in the diagnosis and management of individual
patients.
Dr. Ho-Young Lee, Assistant Professor in the Department of
Nuclear Medicine, Seoul National University, College of Medicine,
SNUBH commented, "We are very excited with the prospects of using
the TexRAD imaging research software platform in conjunction with
the new PET-CT scanner being installed at our institution, further
reinforcing our vision and reputation of being early adopters of
new technologies, particularly in the fascinating area of
quantitative imaging and its applications in cancer care."
TexRAD research software will extract key heterogeneity
information via a novel quantitative texture analysis approach from
SNUBH's cancer imaging datasets. TexRAD has already established
itself as a leading, innovative texture analysis software product,
currently employed as a research tool in a number of prestigious
imaging centres and university hospitals in the UK, EU, and USA.
Similarly it is envisaged that TexRAD will assist in enhancing the
research output in cancer imaging at SNUBH and identify potential
clinical applications and impact on care management of cancer
patients in the future."
Dr. Balaji Ganeshan, Chief Scientist and New Business Officer at
the Company's subsidiaries TexRAD Ltd and Cambridge Computed
Imaging Ltd, commented, "We are delighted to receive this order - a
first on several fronts: Firstly, working with a leading original
equipment manufacturer (OEM) on this sale, bundling TexRAD research
software with the OEM offering and lastly but not least, entry into
the Korean market - particularly the prestigious Seoul National
University Bundang Hospital who are keen to undertake further
exciting research in cancer imaging. This will open up new avenues
and opportunities for Feedback in establishing itself and
fulfilling its vision as an innovative multi-modality medical
imaging software company."
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell / Trevor Brown
/ Tom Charlton
Sanlam Securities UK (Nominated Tel: 020
Adviser and Joint Broker) 7628 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging-Biomarker') in confident decision-making: assessing
the prognosis, disease-severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'.TexRAD is manufactured
under licence by the ISO 13485 certified company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DISZMGZDLVNGKZM
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024